Pan-cancer analysis revealed that low BACH1 expression predicts better outcomes in patients with kidney papillary cell carcinoma, lower grade glioblastoma, hepatocellular carcinoma, pancreatic adenocarcinoma, sarcoma, and thyroid carcinoma. Here, BACH1 is linked to cancer.